Proteomics International Laboratories Ltd (ASX:PIQ)

Market Cap	51.56M
Revenue (ttm)	3.31M
Net Income (ttm)	-8.11M
Shares Out	163.68M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	128,919
Average Volume	308,889
Open	0.3200
Previous Close	0.3200
Day's Range	0.3150 - 0.3250
52-Week Range	0.2850 - 0.9300
Beta	0.05
RSI	33.17
Earnings Date	Aug 21, 2025

About ASX:PIQ

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has comple...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PIQ

Financial Performance

In 2025, ASX:PIQ's revenue was 3.36 million, an increase of 2.41% compared to the previous year's 3.28 million. Losses were -8.11 million, 27.3% more than in 2024.